UPDATED: Celgene pays $1B in landmark deal to buy into Juno’s pipeline of CAR-T drugs

John Carroll Celgene is paying about $ 1 billion to move to the front of the hectic race to build new CAR-T cancer therapies. The Big Biotech is shelling out $ 150 million upfront ...

Bigger pharma may be scraping for good deals, but Horizon has plenty of options, analysts say

Carly Helfand Horizon Pharma isn't exactly the only specialty pharma company hunting for deals. Allergan, Mallinckrodt, Endo and the ever-acquisitive Valeant have all been on shopping ...

Nurse pleads guilty to taking Insys kickbacks as Subsys marketing probe continues

Tracy Staton In an apparent sign that federal prosecutors are zeroing in on the pain-drug maker Insys Therapeutics, a Connecticut nurse and top prescriber has pleaded guilty to accepting ...

Viehbacher returns to lead Swiss billionaire’s $2B biotech fund

Alok Saboo FierceBiotech News

Billionaire Soon-Shiong arranges a $71M crossover round for Conkwest

John Carroll Biotech billionaire Patrick Soon-Shiong is pumping $ 71 million into Conkwest as it preps a move to go public in a $ 172.5 million IPO. FierceBiotech News

Alexion wins EMA nods for not one but two drugs

Eric Palmer Rare-disease specialist Alexion Pharmaceuticals won a double header from the EMA today when the agency recommended approval of two of its drugs, including Kanuma, the enzyme ...

Bristol-Myers is the next big tenant in biotech’s hottest neighborhood

Damian Garde Bristol-Myers Squibb's latest R&D reshuffle calls for a consolidated presence in Cambridge, MA's booming Kendall Square, and the drugmaker has signed on to ...

Merck cancer drugs and Sanofi, Amgen cardio meds have formularies on high alert

Eric Palmer U.S. drug payers have been able to beat back high prices for some COPD and diabetes drugs, much to the chagrin of GlaxoSmithKline and Sanofi. But several new categories ...

Alexion gets EU green light for a pair of rare disease drugs

Damian Garde European regulators are recommending approval for two rare disease treatments from Alexion, a victory for the biotech as it works to expand its stable of commercialized ...

Aquinox’s bladder pain drug misses the mark in Phase II

Damian Garde Aquinox's lead drug failed its main goal in a Phase II trial on bladder pain syndrome, but the company believes its oral treatment showed enough to promise to merit ...

Valeant makes offer for Zoetis, sources tell WSJ

Eric Palmer Rapidly expanding Valeant has approached Zoetis about a buyout, sources told the Wall Street Journal. Rumors of a possible deal, which have been bouncing back and forth ...

Chris Viehbacher explains: “If I had $2 billion to invest…”

John Carroll Not long ago, Viehbacher had a chance to sit down with Ernesto Bertarelli–who made a fortune on the sale of Serono–to pursue a conversation that many people ...
Page 1 of 3123
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS